Cambridge: Vyome Therapeutics, a clinical-stage healthcare company focused on immuno-inflammatory and rare diseases in the US and global markets, has announced the successful completion of its previously disclosed merger with ReShape Lifesciences Inc. (Nasdaq: RSLS).
Following the transaction, the combined entity will operate as Vyome Holdings, Inc. and begin trading on The Nasdaq Stock Market under the ticker symbol HIND from the opening bell on Friday, August 15, 2025.
The listing approval by Nasdaq comes alongside a 1-for-4 reverse stock split of ReShape’s common stock, effective upon market open on August 15. Each four shares of issued and outstanding common stock will convert into one share.
Also Read: CATCH Grant Program Offers AI Innovators in Cancer Care up to INR 1 Crore in Funding
The post-merger CUSIP number will be 92943X104. The reverse split will not alter the agreed ownership distribution between ReShape and Vyome shareholders.
“Nasdaq’s approval is right on track and now we are marching forward to ring the bell on our planned listing date this Friday. We welcome RSLS shareholders and others who wish to join our journey, which will always focus on shareholder value,” said Krishna Gupta, Chairman of Vyome.
“If you believe in the global healthcare market, the US-India innovation corridor, and in science and AI-driven innovation, you believe in Vyome.”
Also Read: Firstsource and Guidehealth Partner to Drive AI-Enabled Value-Based Care for Health Plans
Shiladitya Sengupta, Founder of Vyome and Associate Professor of Medicine at Harvard Medical School, added, “Inflammation is one of the most pressing chronic health challenges today, linked to a market exceeding $100 billion. The company’s clinical-stage assets are aimed at major unmet indications within this space, representing years of dedicated work.”
Vyome Therapeutics: Building a Healthcare Platform to Bridge US-India Innovation Corridor
Vyome Therapeutics is building a healthcare platform that bridges the US-India innovation corridor, with an immediate focus on developing solutions for immuno-inflammatory conditions. The company aims to deliver value through cost-efficient operations while adhering to stringent global quality and safety standards.
